Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, De Boelelaan, 1117, Amsterdam, The Netherlands.
Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, De Boelelaan, 1117, Amsterdam, The Netherlands; Cancer Research UK National Biomarker Centre, University of Manchester, Wilmslow Road, Manchester, UK.
Trends Mol Med. 2024 Jul;30(7):660-672. doi: 10.1016/j.molmed.2024.04.005. Epub 2024 May 1.
Diffuse large B cell lymphoma (DLBCL) exhibits significant biological and clinical heterogeneity that presents challenges for risk stratification and disease surveillance. Existing tools for risk stratification, including the international prognostic index (IPI), tissue molecular analyses, and imaging, have limited accuracy in predicting outcomes. The therapeutic landscape for aggressive lymphoma is rapidly evolving, and there is a pressing need to identify patients at risk of refractory or relapsed (R/R) disease in the context of personalized therapy. Liquid biopsy, a minimally invasive method for cancer signal detection, has been explored to address these challenges. We review advances in liquid biopsy strategies focusing on circulating nucleic acids in DLBCL patients and highlight their clinical potential. We also provide recommendations for biomarker-guided trials to support risk-adapted treatment modalities.
弥漫性大 B 细胞淋巴瘤（DLBCL）表现出显著的生物学和临床异质性，这给风险分层和疾病监测带来了挑战。现有的风险分层工具，包括国际预后指数（IPI）、组织分子分析和影像学，在预测结局方面的准确性有限。侵袭性淋巴瘤的治疗领域正在迅速发展，迫切需要在个性化治疗的背景下识别出有难治性或复发性（R/R）疾病风险的患者。液体活检是一种用于癌症信号检测的微创方法，已经被探索用于解决这些挑战。我们回顾了液体活检策略在 DLBCL 患者中循环核酸方面的进展，并强调了它们的临床潜力。我们还为基于生物标志物的临床试验提供了建议，以支持风险适应的治疗模式。
